Idioma:

Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy

Quintanal-Villalonga, Alvaro ; Taniguchi, Hirokazu ; Hao, Yuan ; Chow, Andrew ; Zhan, Yingqian A ; Chavan, Shweta S ; Uddin, Fathema ; Allaj, Viola ; Manoj, Parvathy ; Shah, Nisargbhai S ; Chan, Joseph M ; Offin, Michael ; Ciampricotti, Metamia ; Ray-Kirton, Jordana ; Egger, Jacklynn ; Bhanot, Umesh ; Linkov, Irina ; Asher, Marina ; Roehrl, Michael H ; Qiu, Juan ; de Stanchina, Elisa ; Hollmann, Travis J ; Koche, Richard P ; Sen, Triparna ; Poirier, John T ; Rudin, Charles M

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (3), p.472-483 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por

Enviar para

Título:
Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy
Autor: Quintanal-Villalonga, Alvaro ; Taniguchi, Hirokazu ; Hao, Yuan ; Chow, Andrew ; Zhan, Yingqian A ; Chavan, Shweta S ; Uddin, Fathema ; Allaj, Viola ; Manoj, Parvathy ; Shah, Nisargbhai S ; Chan, Joseph M ; Offin, Michael ; Ciampricotti, Metamia ; Ray-Kirton, Jordana ; Egger, Jacklynn ; Bhanot, Umesh ; Linkov, Irina ; Asher, Marina ; Roehrl, Michael H ; Qiu, Juan ; de Stanchina, Elisa ; Hollmann, Travis J ; Koche, Richard P ; Sen, Triparna ; Poirier, John T ; Rudin, Charles M
Assuntos: Animals ; Cell Line, Tumor ; Exportin 1 Protein ; Humans ; Karyopherins - metabolism ; Lung Neoplasms - drug therapy ; Lung Neoplasms - pathology ; Mice ; Receptors, Cytoplasmic and Nuclear - metabolism ; Small Cell Lung Carcinoma - drug therapy ; Small Cell Lung Carcinoma - pathology
É parte de: Cancer research (Chicago, Ill.), 2022-02, Vol.82 (3), p.472-483
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
Lead contact
Descrição: Small cell lung cancer (SCLC) is an aggressive malignancy characterized by early metastasis and extreme lethality. The backbone of SCLC treatment over the past several decades has been platinum-based doublet chemotherapy, with the recent addition of immunotherapy providing modest benefits in a subset of patients. However, nearly all patients treated with systemic therapy quickly develop resistant disease, and there is an absence of effective therapies for recurrent and progressive disease. Here we conducted CRISPR-Cas9 screens using a druggable genome library in multiple SCLC cell lines representing distinct molecular subtypes. This screen nominated exportin-1, encoded by , as a therapeutic target. was highly and ubiquitously expressed in SCLC relative to other lung cancer histologies and other tumor types. knockout enhanced chemosensitivity, and exportin-1 inhibition demonstrated synergy with both first- and second-line chemotherapy. The small molecule exportin-1 inhibitor selinexor in combination with cisplatin or irinotecan dramatically inhibited tumor growth in chemonaïve and chemorelapsed SCLC patient-derived xenografts, respectively. Together these data identify exportin-1 as a promising therapeutic target in SCLC, with the potential to markedly augment the efficacy of cytotoxic agents commonly used in treating this disease. SIGNIFICANCE: CRISPR-Cas9 screening nominates exportin-1 as a therapeutic target in SCLC, and exportin-1 inhibition enhances chemotherapy efficacy in patient-derived xenografts, providing a novel therapeutic opportunity in this disease.
Editor: United States
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy

United States

Buscando em bases de dados remotas. Favor aguardar.